13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02239393
(ClinicalTrials.gov)
June 201510/9/2014Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept StudyMEsenchymal Stem Cell Therapy for CAnadian MS PatientsMultiple SclerosisBiological: Mesenchymal Stem CellsOttawa Hospital Research InstituteNULLCompleted18 Years50 YearsAll31Phase 2Canada
2NCT02495766
(ClinicalTrials.gov)
May 11, 20153/6/2015Autologous Mesenchymal Stromal Cells for Multiple SclerosisTreatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple SclerosisRelapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple SclerosisDrug: XCEL-MC-ALPHA;Drug: PlaceboBanc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)Completed18 Years60 YearsAll8Phase 1;Phase 2Spain
3EUCTR2012-000734-19-ES
(EUCTR)
10/04/201410/01/2014Bone marrow cell treatment as treatment of multiple sclerosisTreatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES Multiple Sclerosis
MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: XCEL-MC-ALPHA
Product Code: XCEL-MC-ALPHA
INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved
Other descriptive name: Mesenchymal Stem Cells
Banc de Sang i TeixitsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
4NCT02035514
(ClinicalTrials.gov)
December 201317/12/2013Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisPhase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)Biological: Bone marrow autologous mesenchymal stem cells transplantationGermans Trias i Pujol HospitalMinisterio de Sanidad, Servicios Sociales e IgualdadCompleted18 Years50 YearsBoth9Phase 1;Phase 2Spain
5NCT01730547
(ClinicalTrials.gov)
February 20139/11/2012Mesenchymal Stem Cells for Multiple SclerosisPhase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLRecruiting18 Years50 YearsBoth15Phase 1;Phase 2Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02249676
(ClinicalTrials.gov)
January 201315/9/2014Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersAutologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept StudyDevic's Syndrome;Devic's Neuromyelitis Optica;Devic Syndrome;Devic's Disease;Devic DiseaseBiological: Autologous mesenchymal stem cellsTianjin Medical University General HospitalNULLCompleted18 Years80 YearsAll15Phase 2China
7NCT03778333
(ClinicalTrials.gov)
December 1, 201214/1/2015Mesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenMesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenAutologous Mesenchymal Stem Cells;Multiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLCompleted18 Years65 YearsAll7Phase 1Sweden
8NCT01895439
(ClinicalTrials.gov)
October 201224/6/2013Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple SclerosisPhase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional TreatmentMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsUniversity of JordanNULLCompleted18 Years65 YearsAll13Phase 1;Phase 2Jordan
9NCT01854957
(ClinicalTrials.gov)
July 20128/5/2013MEsenchymal StEm Cells for Multiple SclerosisMEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsAntonio UccelliAzienda Ospedaliera Universitaria Integrata Verona;Ospedale San RaffaeleRecruiting18 Years50 YearsBoth20Phase 1;Phase 2Italy
10NCT01228266
(ClinicalTrials.gov)
December 201025/10/2010Mesenchymal Stem Cell Transplantation in MSAutologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II StudyMultiple SclerosisBiological: autologous mesenchymal stem cellsAlbert SaizInstituto de Salud Carlos IIITerminated18 Years50 YearsBoth9Phase 2Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2015-000137-78-AT
(EUCTR)
17/09/2015Mesenchymal stem cells therapy for patients with multiple sclerosisRandomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria) multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Human autologous mesenchymal stem cells
INN or Proposed INN: MSC2015
Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS
SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMUNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Austria